A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

NCT04457180 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Apatinib Mesylate
DRUG: Repaglinide
DRUG: Bupropion

Sponsor

Jiangsu HengRui Medicine Co., Ltd.